Boehringer Ingelheim and Sarah Cannon to assess new cancer therapy

Boehringer Ingelheim has announced a new cancer-focused research collaboration with the Sarah Cannon Research Institute.

The companies will be expanding their strategic partnership to carry out a clinical trial evaluating BI 891065, a novel and potent SMAC mimetic, both alone and in combination with PD-1-directed cancer therapies.

SMAC mimetics are a new class of targeted, small molecules that trigger tumour cell death and immune system activation, meaning they can potentially enhance the activity of immunotherapies in the treatment of cancer.

BI 891065 will be studied in a phase I clinical trial alone and in combination with BI 754091 in patients with advanced metastatic solid tumours. The first patient has already been enrolled in the phase I study, which aims to include approximately 100 patients.

This collaboration will bring together Boehringer Ingelheim's oncology research knowledge and Sarah Cannon's expertise in clinical trial design and recruitment.

Dr Mehdi Shahidi, global medical head of oncology at Boehringer Ingelheim, said: "We are extremely proud to be one of the first companies to bring this innovative combination therapy of an immune checkpoint inhibitor and a small molecule targeted treatment to the clinical stage of development."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.